Saatchi Mohammad, Mansournia Mohammad Ali, Khalili Davood, Daroudi Rajabali, Yazdani Kamran
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Risk Manag Healthc Policy. 2020 Aug 5;13:1015-1028. doi: 10.2147/RMHP.S265887. eCollection 2020.
An area of interest to health policymakers is the effect of interventions aimed at risk factors on decreasing the number of new cardiovascular disease (CVD) cases. The aim of this study was to estimate the generalized impact fraction (GIF) and population attributable fraction (PAF) of hypertension (HTN) for CVD in Tehran.
In this population-based cohort study, 8071 participants aged ≥30 years were followed for a median of 16 years. A survival model was used to estimate the 10- and 18-year risk of CVD. JNC-IV and 2017 ACC/AHA guidelines were used to categorize blood pressure (BP). PAF and GIF were estimated in different scenarios using the parametric G-formula.
Of 7378 participants included in analyses, 22.7% and 52.3% were classified as hypertensive according to the JNC-IV and 2017 ACC/AHA guidelines, respectively. According to the 2017 ACC/AHA, the 10-year risk of CVD was 5.1% (4.3-6.0%), 8.9% (6.7-12.0%), and 7.1% (6.1-8.4%) for normal BP, elevated BP, and stage 1 HTN, respectively, and 20.8% (18.8-23.0%) for stage 2 of the 2017 ACC/AHA and JNC-IV. The PAF of stage 2 vs stage 1 and vs normal BP for CVD was 17.4% (11.5-21.8%) and 20.4% (14.6-26.4%), respectively. The GIF of 30% reduction in the prevalence of stage 2 HTN to stage 1 and to normal BP for CVD was 5.1% (3.4-6.6%) and 6.1% (4.4-8.0%), respectively. Based on JNC-IV, the PAF and GIF of 30% for CVD were 17.8% (12.7-22.9%) and 5.4% (4.0-6.9%), respectively.
By reducing the prevalence of HTN by 30%, a remarkable number of new CVD cases would be prevented. In an Iranian population, the comparison of HTN cases with normal BP showed no association between stage 1 HTN and CVD, whereas elevated BP was a significant risk factor for the incidence of CVD.
健康政策制定者感兴趣的一个领域是针对风险因素的干预措施对减少新的心血管疾病(CVD)病例数的影响。本研究的目的是估计德黑兰高血压(HTN)对CVD的广义影响分数(GIF)和人群归因分数(PAF)。
在这项基于人群的队列研究中,对8071名年龄≥30岁的参与者进行了为期16年的中位数随访。使用生存模型估计CVD的10年和18年风险。采用美国国家联合委员会第4版(JNC-IV)和2017年美国心脏病学会/美国心脏协会(ACC/AHA)指南对血压(BP)进行分类。使用参数化G公式在不同情况下估计PAF和GIF。
在纳入分析的7378名参与者中,根据JNC-IV和2017年ACC/AHA指南,分别有22.7%和52.3%的人被归类为高血压患者。根据2017年ACC/AHA指南,正常血压、血压升高和1期HTN患者的CVD 10年风险分别为5.1%(4.3 - 6.0%)、8.9%(6.7 - 12.0%)和7.1%(6.1 - 8.4%),2017年ACC/AHA指南2期和JNC-IV 2期患者的CVD 10年风险为20.8%(18.8 - 23.0%)。CVD 2期与1期以及与正常血压相比的PAF分别为17.4%(11.5 - 21.8%)和20.4%(14.6 - 26.4%)。将2期HTN患病率降低30%至1期和正常血压水平时,CVD的GIF分别为5.1%(3.4 - 6.6%)和6.1%(4.4 - 8.0%)。基于JNC-IV,CVD的PAF和GIF分别为17.8%(12.7 - 22.9%)和5.4%(4.0 - 6.9%)。
将HTN患病率降低30%,可预防大量新的CVD病例。在伊朗人群中,HTN病例与正常血压的比较显示,1期HTN与CVD之间无关联,而血压升高是CVD发病的一个重要危险因素。